神经科学学会——第39届年会。第一部分——中枢神经系统疾病和疼痛的新型治疗方法。

Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.

作者信息

Al-Shamahi Asma, Kirkham Konrad, Hookes Livia

机构信息

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

出版信息

IDrugs. 2009 Dec;12(12):731-3.

PMID:19943210

Abstract

The 39th Annual Meeting of the Society for Neuroscience (SFN), held in Chicago, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on nicotinic ACh receptor alpha7 agonists, cannabinoid CB2 receptor agonists, transient receptor potential channel antagonists, spinal mechanotransmission modulation, a COX-1 inhibitor, a NaV/CaV blocker, an opioid modulator and a novel triple reuptake inhibitor with potential antidepressant, anxiolytic and analgesic activity. Investigational drugs discussed include JN-711 (Novartis AG), NESS-070C5 and NESS-080C5 (both being developed by CeNeRx BioPharma Inc), RQ-00203078 (RaQualia Pharma Inc), HC-030031 (Cubist Pharmaceuticals Inc/Hydra Biosciences Inc), A-967079 (Abbott Laboratories), TRL-382 (Toray Industries Inc), NP-A (Neuromed Pharmaceuticals Inc) and RDC-5768 (Alkermes Inc).

摘要

在芝加哥举行的第39届神经科学学会（SFN）年会涵盖了神经科学领域新治疗进展的诸多主题。本会议报告重点介绍了有关烟碱型乙酰胆碱受体α7激动剂、大麻素CB2受体激动剂、瞬时受体电位通道拮抗剂、脊髓机械传导调制、一种COX - 1抑制剂、一种钠通道/钙通道阻滞剂、一种阿片类调节剂以及一种具有潜在抗抑郁、抗焦虑和镇痛活性的新型三重再摄取抑制剂的部分报告。所讨论的研究药物包括JN - 711（诺华公司）、NESS - 070C5和NESS - 080C5（均由CeNeRx生物制药公司研发）、RQ - 00203078（RaQualia制药公司）、HC - 030031（立方制药公司/九头蛇生物科学公司）、A - 967079（雅培实验室）、TRL - 382（东丽工业公司）、NP - A（Neuromed制药公司）以及RDC - 5768（阿尔克姆斯公司）。